Table 1.
Baseline characteristics of biologic-treated patients with ulcerative colitis included in cohort
| Baseline characteristics | Normal BMI (18.5-24.9kg/m2) |
Overweight (25.0-29.9kg/m2) |
Obese (≥30kg/m2) |
|---|---|---|---|
|
| |||
| Number of patients | 90 (56.3%) | 41 (25.6%) | 29 (18.1%) |
|
| |||
| PATIENT CHARACTERISTICS | |||
|
| |||
| Age at cohort entry, in years (median, IQR) | 31.0 (24.0-45.8) | 43.0 (31.5-53.0) | 40.0 (29.0-54.5) |
|
| |||
| Gender – Males/Females | 36/54 | 28/13 | 16/13 |
|
| |||
| Follow up, months (median, IQR) | 22.0 (14.5-36.7) | 28.5 (19.6-34.3) | 20.8 (14.1-31.7) |
|
| |||
| Body mass index (kg/m2) (median, IQR) | 21.6 (20.4-23.2) | 27.4 (26.0-28.7) | 35.2 (32.2-40.9) |
|
| |||
| Smoking status (%) | |||
| • Current smokers | 4 (4.4) | 2 (4.9) | 2 (6.9) |
| • Recent past smoker (<1 y from cohort entry) | 1 (1.1) | 0 (0) | 1 (3.4) |
| • Former smokers | 14 (15.6) | 16 (39.0) | 9 (31.0) |
| • Never smoker | 71 (78.9) | 23 (56.1) | 17 (58.6) |
|
| |||
| DISEASE CHARACTERISTICS | |||
|
| |||
| Disease duration at cohort entry, in years (median, IQR) | 4.0 (1.0-8.0) | 5.0 (2.0-11.5) | 4.0 (1.0-7.5) |
|
| |||
| Disease extent, N (%) | |||
| • Extensive colitis | 59 (65.6) | 19 (46.3) | 20 (69.0) |
| • Left-sided colitis | 30 (33.3) | 22 (53.7) | 9 (31.0) |
| • Proctitis | 1 (1.1) | 0 (0) | 0 (0) |
|
| |||
| Disease severity* (%) | |||
| • Mayo score 0 | 0 (0) | 1 (4.3) | 0 (0) |
| • Mayo score 1 | 10 (18.5) | 0 (0) | 0 (0) |
| • Mayo score 2 | 13 (24.1) | 6 (26.1) | 8 (53.3) |
| • Mayo score 3 | 31 (57.4) | 16 (69.6) | 7 (46.7) |
|
| |||
| Prior IBD hospitalization <1 y from cohort entry (%) | 33/90 (36.7) | 8/41 (19.5) | 3/29 (10.3) |
|
| |||
| TREATMENT CHARACTERISTICS | |||
|
| |||
| Anti-TNF taken at cohort entry (%) | |||
| • Infliximab | 49 (54.4) | 23 (56.1) | 16 (55.2) |
| • Adalimumab | 19 (21.1) | 5 (12.2) | 7 (24.1) |
| • Golimumab | 6 (6.7) | 4 (9.8) | 0 (0) |
| • Certolizumab pegol | 0 (0.0) | 1 (2.4) | 0 (0) |
| • Vedolizumab | 16 (17.8) | 8 (19.5) | 6 (20.7) |
|
| |||
| # of prior anti-TNF failures | |||
| • 0 | 71 (78.9) | 29 (70.7) | 17 (58.6) |
| • 1 | 16 (17.8) | 8 (19.5) | 10 (34.5) |
| • 2 | 2 (2.2) | 4 (9.8) | 2 (6.9) |
| • 3 | 1 (1.1) | 0 (0) | 0 (0) |
|
| |||
| Prior steroid use <1 year from cohort entry (%) | 74 (82.2) | 34 (82.9) | 22 (75.9) |
|
| |||
| Steroid use at cohort entry (%) | 46 (51.1) | 22 (53.7) | 15 (51.7) |
|
| |||
| Prior use of immunomodulators (%) | 47 (52.2) | 20 (48.8) | 18 (62.1) |
|
| |||
| Immunomodulator use at cohort entry (%) | |||
| • Azathioprine | 30 (63.8) | 17 (65.4) | 7 (43.75) |
| • 6-mercaptopurine | 11 (23.4) | 8 (30.8) | 7 (43.75) |
| • Methotrexate | 6 (12.8) | 1 (3.8) | 2 (12.5) |
|
| |||
| C-reactive protein, g/L (median, IQR) | 0.002 (0.001-0.013) | 0.007 (0.003-0.027) | 0.003 (0.002-0.006) |
|
| |||
| Albumin, g/L (median, IQR) | 40.0 (37.0-43.0) | 41.0 (37.0-42.3) | 41.0 (39.0-44.0) |
|
| |||
| Hemoglobin, g/L (mean, SD) | 120 (21) | 125 (22) | 126 (20) |
|
| |||
| Erythrocyte sedimentation rate, mm/hr (median, IQR) | 15.5 (6.0-30.0) | 18.5 (6.0-42.3) | 11.0 (7.0-18.8) |
*
Data available for 92/160 patients [54 patients with normal BMI, 23 overweight patients, 15 obese patients]
[Abbreviations: BMI=Body mass index, IQR=Interquartile range, IBD=Inflammatory bowel disease, TNF=Tumour necrosis factor]